Georgi Yordanov is an investment analyst in health care, covering small- and mid-cap biotech stocks, in the U.S. Equity Division of T. Rowe Price Investment Management. 

Georgi’s investment experience began in 2019, and he has been with T. Rowe Price since 2023, beginning in the U.S. Equity Division. Prior to this, Georgi was employed by Cowen as a lead senior analyst in the area of health care equity research. Georgi also consulted with The Solution Lab, conducting competitive analysis in the emerging therapeutic space, and served as a research intern in the area of oncology with the DNA Damage Response Group at AstraZeneca.

Georgi earned a Ph.D. in biological sciences, with a focus on oncology, from the Watson School of Biological Sciences, Cold Spring Harbor Laboratory, where he was awarded the Boehringer Ingelheim Fonds Ph.D. fellowship. He also earned a B.Sc. (honors) in molecular biology from the University of Liverpool in the UK.